$49.1 B

Novartis Revenue FY, 2017
Novartis Revenue growth (FY, 2016 - FY, 2017), %1%
Novartis Gross profit (FY, 2017)31.9 B
Novartis Gross profit margin (FY, 2017), %65%
Novartis Net income (FY, 2017)7.7 B
Novartis Cash, 31-Dec-20178.9 B

Novartis Revenue

Novartis revenue was $49.11 b in FY, 2017 which is a 1.2% year over year increase from the previous period.

Embed Graph

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 12.3% from Alcon, 20.5% from Sandoz and 67.2% from Innovative Medicines

Novartis revenue breakdown by geographic segment: 6.5% from Japan , 5.1% from France, 7.5% from Germany, 34.5% from United States and 46.5% from Other

Novartis Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

53.6b49.4b48.5b49.1b

Revenue growth, %

(8%)(2%)1%

Cost of goods sold

17.3b17.4b17.5b17.2b

Gross profit

36.3b32.0b31.0b31.9b

Gross profit Margin, %

68%65%64%65%

Sales and marketing expense

12.4b11.8b12.0b12.9b

R&D expense

9.1b8.9b9.0b9.0b

General and administrative expense

2.6b2.5b2.2b2.1b

Operating expense total

25.2b24.0b23.6b24.3b

Interest expense

704.0m655.0m707.0m777.0m

Pre tax profit

8.1b7.8b9.0b

Income tax expense

1.1b1.1b1.3b

Net Income

10.3b17.8b6.7b7.7b

Novartis Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

7.0b8.9b

Accounts Receivable

8.2b8.6b

Inventories

6.3b6.9b

Current Assets

24.9b28.2b

PP&E

15.6b16.5b

Goodwill

31.0m31.8b

Total Assets

130.1b133.1b

Accounts Payable

4.9b5.2b

Current Liabilities

22.2b23.4b

Non-Current Liabilities

33.0b35.4b

Total Liabilities

55.2b58.9b

Common Stock

972.0m969.0m

Total Equity

74.9b74.2b

Financial Leverage

1.7 x1.8 x

Novartis Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

7.0b6.7b7.7b

Cash From Operating Activities

11.9b11.5b12.6b

Purchases of PP&E

(2.4b)(1.9b)(1.7b)

Cash From Investing Activities

(10.8b)(3.4b)(3.1b)

Short-term Borrowings

(755.0m)

Long-term Borrowings

(3.1b)(1.7b)(188.0m)

Dividends Paid

(6.6b)(6.5b)(6.5b)

Cash From Financing Activities

(9.2b)(5.3b)(7.7b)

Net Change in Cash

(8.3b)2.3b1.9b

Novartis Ratios

USDY, 2017

Revenue/Employee

405.5k

Financial Leverage

1.8 x
Report incorrect company information

Novartis Operating Metrics

Y, 2015Y, 2016

Major Approvals (US, EU, JP)

20 16

Major Submissions (US, EU, JP)

14 24

Patients Reached

972 m965 m

Phase III Trials Products

37 29

Projects Entering Development Pipeline

8 5

US FDA Breakthrough Therapy Designations

5
Report incorrect company information

Novartis Employee Rating

3.72640 votes
Culture & Values
3.6
Work/Life Balance
3.6
Senior Management
3.0
Salary & Benefits
3.7
Career Opportunities
3.3
Source